All Outputs (57)

P087 Cardioprotective effects of colchicine in people with gout: a systematic review (2025)
Presentation / Conference Contribution
Prior, J. A., Umar, Z., Ibrahim, N., Bajpai, R., Partington, R., Mamas, M., & Roddy, E. (2025, April). P087 Cardioprotective effects of colchicine in people with gout: a systematic review. Poster presented at British Society for Rheumatology Annual Conference 2025, Manchester Central Convention Complex, Manchester, England UK

Background/Aims Colchicine is widely used in clinical practice to prevent and treat gout flares. Randomised controlled trials (RCT) have demonstrated cardiovascular benefits of colchicine in people with chronic coronary artery disease (CAD) or a rece... Read More about P087 Cardioprotective effects of colchicine in people with gout: a systematic review.

OA01 Long-term cardiovascular safety of febuxostat compared with allopurinol or no urate-lowering treatment in people with gout: a cohort study in UK primary care using the Clinical Practice Research Datalink (2025)
Presentation / Conference Contribution
Partington, R., Muller, S., Mallen, C. D., Mamas, M. A., Forrester, H., & Roddy, E. (2025, April). OA01 Long-term cardiovascular safety of febuxostat compared with allopurinol or no urate-lowering treatment in people with gout: a cohort study in UK primary care using the Clinical Practice Research Datalink. Presented at British Society for Rheumatology Annual Conference, Manchester Central Convention Complex, Manchester, England

Background/Aims Febuxostat is recommended as first line urate-lowering therapy (ULT) for gout in the UK. However, concerns were raised regarding its cardiovascular (CV) safety. Current guidance advises caution when using it in people with CV disease,... Read More about OA01 Long-term cardiovascular safety of febuxostat compared with allopurinol or no urate-lowering treatment in people with gout: a cohort study in UK primary care using the Clinical Practice Research Datalink.

Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform (2024)
Presentation / Conference Contribution
Russell, M., Massey, J., Roddy, E., MacKenna, B., Bacon, S., Goldacre, B., Andrews, C., Hickman, G., Mehrkar, A., Mahto, A., Rutherford, A., Patel, S., Adas, M., Alveyn, E., Nagra, . D., Bechman, K., Ledingham, J., Hudson, J., Norton, S., Cope, A., & Galloway, J. (2024, November). Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform. Poster presented at Abstract Supplement ACR Convergence 2024, Washington DC

Background/Purpose: Data from before the COVID-19 pandemic had shown persistently poor care for people with gout in many countries worldwide. Whether this was further exacerbated by the pandemic is not fully understood. Our objective was to investiga... Read More about Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform.

AB0105 ‘..THERE’S TOO MUCH TO PUT IN A LEAFLET’: A QUALITATIVE EXPLORATION OF STAKEHOLDER VIEWS OF LIFESTYLE INTERVENTIONS FOR GOUT (2024)
Presentation / Conference Contribution
Watson, L., Cornwall, N., Jinks, C., Bradbury, K., Goff, L., Little, P., Mallen, C., & Roddy, E. (2024, June). AB0105 ‘..THERE’S TOO MUCH TO PUT IN A LEAFLET’: A QUALITATIVE EXPLORATION OF STAKEHOLDER VIEWS OF LIFESTYLE INTERVENTIONS FOR GOUT. Paper presented at EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria, Vienna

Background: Lifestyle has been associated with gout for centuries and dietary triggers of flares remain of great interest to people with gout. However, there is a lack of robust clinical trial evidence about the eff... Read More about AB0105 ‘..THERE’S TOO MUCH TO PUT IN A LEAFLET’: A QUALITATIVE EXPLORATION OF STAKEHOLDER VIEWS OF LIFESTYLE INTERVENTIONS FOR GOUT.

P086 Trends in the Incidence and Management of Gout in England: A Nationwide Study using the OpenSAFELY Platform (2024)
Presentation / Conference Contribution
Russell, M. D., Massey, J., Roddy, E., MacKenna, B., Bacon, S., Goldacre, B., Andrews, C. D., Hickman, G., Mehrkar, A., Mahto, A., Rutherford, A. I., Patel, S., Adas, M. A., Alveyn, E., Nagra, D., Bechman, K., Ledingham, J. M., Hudson, J., Norton, S., Cope, A., & Galloway, J. (2024, April). P086 Trends in the Incidence and Management of Gout in England: A Nationwide Study using the OpenSAFELY Platform. Poster presented at British Society for Rheumatology Annual Conference 2024

Background/Aims Gout is the most common inflammatory arthritis worldwide, yet one of the worst managed. Few population-level studies have evaluated how the COVID-19 pandemic impacted on incidence, prevalence, management and hospitalisations for peopl... Read More about P086 Trends in the Incidence and Management of Gout in England: A Nationwide Study using the OpenSAFELY Platform.

P085 Implementing treat-to-target urate-lowering therapy during hospitalisations for gout flares: a prospective cohort study (2024)
Presentation / Conference Contribution
Russell, M. D., Ameyaw-Kyeremeh, L., Dell'Accio, F., Lapham, H., Head, N., Stovin, C., Patel, V., Clarke, B., Nagra, D., Alveyn, E., Adas, M. A., Bechman, K., de la Puente, M. A., Ellis, B., Byrne, C., Patel, R., Rutherford, A. I., Cantle, F., Norton, S., Roddy, E., …Galloway, J. B. (2024, April). P085 Implementing treat-to-target urate-lowering therapy during hospitalisations for gout flares: a prospective cohort study. Poster presented at British Society for Rheumatology Annual Conference 2024

Background/Aims Hospitalisations for gout flares have doubled in England during the last 15 years. Despite this, no studies have evaluated strategies designed to increase the uptake of urate-lowering therapy (ULT) in people hospitalised for gout flar... Read More about P085 Implementing treat-to-target urate-lowering therapy during hospitalisations for gout flares: a prospective cohort study.

269 CLINICAL GUIDELINE RESEARCH RECOMMENDATIONS FOR THE NON-SURGICAL MANAGEMENT OF OSTEOARTHRITIS: A THEMATIC SYNTHESIS. (2024)
Presentation / Conference Contribution
Woodcock, C., English, E., Jinks, C., Healey, E. L., Parry, E., Paskins, Z., Roddy, E., Simkins, J., Thomas, M., Bennell, K., Hinman, R. S., & Holden, M. (2024, April). 269 CLINICAL GUIDELINE RESEARCH RECOMMENDATIONS FOR THE NON-SURGICAL MANAGEMENT OF OSTEOARTHRITIS: A THEMATIC SYNTHESIS. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria

POS0508 A RANDOMISED CONTROLLED TRIAL COMPARING ANAKINRA VERSUS STEROIDS FOR THE TREATMENT OF GOUT ATTACKS IN PEOPLE WITH RENAL DISEASE (ASGARD): A FEASIBILITY STUDY (2023)
Presentation / Conference Contribution
Balasubramaniam, G., Almond, M., Harnett, P., Zhang, J., Turner, D., Scales, J., Moore, C., Hayden, K., Roddy, E., Mallen, C., Ng, N., Bhagat, S., Rutherford, A., & Dasgupta, B. (2023, May). POS0508 A RANDOMISED CONTROLLED TRIAL COMPARING ANAKINRA VERSUS STEROIDS FOR THE TREATMENT OF GOUT ATTACKS IN PEOPLE WITH RENAL DISEASE (ASGARD): A FEASIBILITY STUDY. Presented at EULAR 2023 European Congress of Rheumatology, Milan, Italy

Background Title: A study to determine the feasibility of undertaking a definitive randomised multi-centre, double-blind, double-dummy controlled study of Anakinra vs. intramuscular methylprednisolone acetate for ac... Read More about POS0508 A RANDOMISED CONTROLLED TRIAL COMPARING ANAKINRA VERSUS STEROIDS FOR THE TREATMENT OF GOUT ATTACKS IN PEOPLE WITH RENAL DISEASE (ASGARD): A FEASIBILITY STUDY.

BARRIERS AND FACILITATORS TO LIFESTYLE CHANGE IN PEOPLE LIVING WITH GOUT: A SCOPING REVIEW OF QUALITATIVE STUDIES (2023)
Presentation / Conference Contribution
Watson, L., Cornwall, N., Jinks, C., Bradbury, K., Goff, L., Little, P., Mallen, C. D., & Roddy, E. (2023, April). BARRIERS AND FACILITATORS TO LIFESTYLE CHANGE IN PEOPLE LIVING WITH GOUT: A SCOPING REVIEW OF QUALITATIVE STUDIES. Poster presented at British Society for Rheumatology Annual Conference 2023, Manchester Central Convention Complex, Manchester, UK

P102 Barriers and facilitators to lifestyle change in people living with gout: a scoping review of qualitative studies (2023)
Presentation / Conference Contribution
Watson, L., Cornwall, N., Jinks, C., Bradbury, K., Goff, L., Little, P., Mallen, C. D., & Roddy, E. (2023, April). P102 Barriers and facilitators to lifestyle change in people living with gout: a scoping review of qualitative studies. Poster presented at British Society for Rheumatology Annual Conference 2023, Manchester Central Convention Complex, Manchester, UK

Background/Aims
Lifestyle, especially diet and alcohol, has been implicated in the causation of gout for centuries and the dietary factors which may trigger flares remain of great interest to people living with gout and their families. However, ther... Read More about P102 Barriers and facilitators to lifestyle change in people living with gout: a scoping review of qualitative studies.

P203 Comparison of coding of giant cell arteritis in primary and secondary care records: an observational feasibility study (2023)
Presentation / Conference Contribution
Padmanabhan, N., Muller, S., Bailey, J., Helliwell, T., Mackie, S. L., Mallen, C. D., & Roddy, E. (2023, April). P203 Comparison of coding of giant cell arteritis in primary and secondary care records: an observational feasibility study. Poster presented at British Society for Rheumatology Annual Conference 2023, Manchester Central Convention Complex, Manchester, UK

Giant cell arteritis (GCA) is considered a medical emergency, and relapses are common, affecting around 50% of patients. Many of the early symptoms of GCA are non-specific and highly prevalent in older people, making the diagnosis challenging.

The... Read More about P203 Comparison of coding of giant cell arteritis in primary and secondary care records: an observational feasibility study.

Structural Foot Characteristics In People With Midfoot Osteoarthritis (2023)
Presentation / Conference Contribution
Lithgow, M., Buldt, A., Munteanu, S., Marshall, M., Thomas, M., Peat, G., Roddy, E., & Menz, H. Structural Foot Characteristics In People With Midfoot Osteoarthritis. Presented at 2023 OARSI World Congress on Osteoarthritis (17-20 March 2023)

what factors require consideration when individualising exercise interventions for people with osteoarthritis? Consensus of experts using a delphi methodology (2023)
Presentation / Conference Contribution
Yaseen, K., Zhang, W., Doherty, M., Abhishek, A., Jamtvedt, G., Martinez, M., Walsh, N., Roddy, E., Callaghan, M., Goh, S., Smith, T., Holden, M., Sala, D., Hall, M., Allen, K., Lee, E., Mallen, C., Conaghan, P., & Hall, M. (2023, March). what factors require consideration when individualising exercise interventions for people with osteoarthritis? Consensus of experts using a delphi methodology. Poster presented at 2023 OARSI World Congress on Osteoarthritis, Sheraton Denver Downtown Hotel, Denver, USA

A Genome-Wide Association Analysis of 2,622,830 Individuals Reveals New Pathogenic Pathways in Gout (2022)
Presentation / Conference Contribution
Merriman, T., Matsuo, H., Takei, R., Leask, M., Topless, R., Shirai, Y., Li, Z., Cadzow, M., Reynolds, R., Saag, K., Fadason, T., O'Sullivan, J., Dalbeth, N., Stamp, L., Abhishek, A., Doherty, M., Roddy, E., Jacobsson, L., Kapetanovic, M., Andrès, M., …Major, T. (2022, November). A Genome-Wide Association Analysis of 2,622,830 Individuals Reveals New Pathogenic Pathways in Gout. Presented at ACR Convergence 2022

Background/Purpose: Genome-wide association studies (GWAS) in gout have been relatively small (≤13,179 people with gout) and have provided little insight into the progression from hyperuricemia to gout. We present a gout GWAS that includes 120,282 pe... Read More about A Genome-Wide Association Analysis of 2,622,830 Individuals Reveals New Pathogenic Pathways in Gout.

Evaluating the long-term effect of allopurinol use in gout using marginal structural models: A primary care electronic health records study (2022)
Presentation / Conference Contribution
Rathod-Mistry, T., Roddy, E., Jordan, K., Mallen, C., & Blagojevic-Bucknall, M. (2022, August). Evaluating the long-term effect of allopurinol use in gout using marginal structural models: A primary care electronic health records study

Background: Allopurinol is intended to be taken for life in the treatment of gout. In UK primary care, treatment is suboptimal with up to 30% of indicated patients being treated within five years of diagnosis and once prescribed allopurinol, treatmen... Read More about Evaluating the long-term effect of allopurinol use in gout using marginal structural models: A primary care electronic health records study.

P145 Safety of colchicine or NSAID prophylaxis when initiating allopurinol for gout: propensity score-matched cohort studies (2022)
Presentation / Conference Contribution
Roddy, E., Bajpai, R., Forrester, H., Partington, R., Mallen, C. D., Clarson, L., Padmanabhan, N., Whittle, R., & Muller, S. P145 Safety of colchicine or NSAID prophylaxis when initiating allopurinol for gout: propensity score-matched cohort studies

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background/Aims</jats:title> <jats:p>Initiating urate-lowering therapy for gout commonly triggers a gout flare and hence co-prescription of colchicine or non-steroidal anti-inflammatory drug (N... Read More about P145 Safety of colchicine or NSAID prophylaxis when initiating allopurinol for gout: propensity score-matched cohort studies.

P182 Health literacy and gout characteristics in a primary care cohort (2022)
Presentation / Conference Contribution
Watson, L., Protheroe, J., Mallen, C., Muller, S., & Roddy, E. P182 Health literacy and gout characteristics in a primary care cohort

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background/Aims</jats:title> <jats:p>Gout is the most common inflammatory arthritis, affecting 2.5% of the UK population. It is often suboptimally managed, despite the availability of effective... Read More about P182 Health literacy and gout characteristics in a primary care cohort.

CLINICAL AND COST-EFFECTIVENESS OF ULTRASOUND-GUIDED INTRA-ARTICULAR CORTICOSTEROID AND LOCAL ANAESTHETIC INJECTION FOR HIP OSTEOARTHRITIS: A RANDOMISED CONTROLLED TRIAL (HIT) (2020)
Presentation / Conference Contribution
Paskins, Z., Bromley, K., Lewis, M., Hughes, G., Hughes, E., Cherrington, A., Hall, A., Holden, M., Oppong, R., Kigozi, J., Stevenson, K., Menon, A., Roberts, P., Peat, G., Jinks, C., Foster, N., Mallen, C., & Roddy, E. CLINICAL AND COST-EFFECTIVENESS OF ULTRASOUND-GUIDED INTRA-ARTICULAR CORTICOSTEROID AND LOCAL ANAESTHETIC INJECTION FOR HIP OSTEOARTHRITIS: A RANDOMISED CONTROLLED TRIAL (HIT). Presented at British Society for Rheumatology Annual Conference 2020 (30 April 2020 - 03 May 2020)

Identification of radiographic foot osteoarthritis: are both dorsoplantar and lateral x-rays necessary? (2020)
Presentation / Conference Contribution
Menz, H., Marshall, M., Thomas, M., Peat, G., & Roddy, E. Identification of radiographic foot osteoarthritis: are both dorsoplantar and lateral x-rays necessary?. Presented at 2020 OARSI World Congress on Osteoarthritis; 30 April-3 May 2020, Messe Wien Exhibition & Congress Center, Vienna, Austria

Purpose: The La Trobe radiographic atlas of foot osteoarthritis (OA), which was developed in 2009 to standardise the assessment of foot OA, incorporates observations of osteophytes (OP) and joint space narrowing (JSN) from dorsoplantar (DP) and later... Read More about Identification of radiographic foot osteoarthritis: are both dorsoplantar and lateral x-rays necessary?.

The hip injection trial (HIT) nested qualitative study: experiences of living with hip Osteoarthritis and receiving trial treatments. (2020)
Presentation / Conference Contribution
Holden, M., Hawarden, A., Paskins, Z., Roddy, E., Mallen, C., Jinks, C., & Trial Team, T. H. The hip injection trial (HIT) nested qualitative study: experiences of living with hip Osteoarthritis and receiving trial treatments. Presented at 2020 OARSI World Congress on Osteoarthritis; 30 April-3 May 2020, Messe Wien Exhibition & Congress Center, Vienna, Austria

Purpose: Evidence about the effectiveness of intra-articular corticosteroid injection for hip osteoarthritis (OA) is limited. The HIT trial compared ultrasound-guided intra-articular hip injection (USGI) of triamcinolone acetonide and 1% lidocaine hy... Read More about The hip injection trial (HIT) nested qualitative study: experiences of living with hip Osteoarthritis and receiving trial treatments..